The hypoxic bone marrow (BM) microenvironment confers growth/survival and drug resistance in multiple myeloma (MM) cells. Novel therapies targeting the MM cell in its hypoxic BM milieu may overcome drug resistance. Recent studies led to the development of a novel molecule RRx-001 with hypoxia-selective epigenetic and nitric oxide-donating properties. Here, we demonstrate that RRx-001 decreases the viability of MM cell lines and primary patient cells, as well as overcomes drug resistance. RRx-001 inhibits MM cell growth in the presence of BM stromal cells. RRx-001-induced apoptosis is associated with: (i) activation of caspases; (ii) release of ROS and nitrogen species; (iii) induction of DNA damage via ATM/γ-H2AX; and (iv) decrease in DNA methyltransferase (DNMT) and global methylation. RNA interference study shows a predominant role of DNMT1 in MM cell survival versus DNMT3a or DNMT3b. The deubiquitylating enzyme USP7 stimulates DNMT1 activity, and conversely, USP7-siRNA reduced DNMT1 activity and decreased MM cell viability. RRx-001 plus USP7 inhibitor P5091 triggered synergistic anti-MM activity. MM xenograft studies show that RRx-001 is well tolerated, inhibits tumor growth and enhances survival. Combining RRx-001 with pomalidomide, bortezomib or SAHA induces synergistic anti-MM activity. Our results provide the rationale for translation of RRx-001, either alone or in combination, to clinical evaluation in MM.
INTRODUCTION
Multiple myeloma (MM) remains incurable in many cases despite novel therapies, highlighting the need for further identification of factors in the host-MM bone marrow (BM) microenvironment that mediate tumorigenesis and drug resistance. 1, 2 The hypoxic BM microenvironment 3 confers epigenetic alterations in MM cells and promotes both angiogenesis and metastasis. [4] [5] [6] DNA methylation is a major epigenetic mechanism that: (i) modulates the expression of tumor suppressor genes; (ii) maintains genomic integrity; and (iii) have a critical role in initiation and progression of cancers, including MM. [7] [8] [9] Recent studies show that alterations in DNA methylation induce MM cell growth and drug resistance. 10 Importantly, DNA hypermethylation of genes is associated with the progression of monoclonal gammopathy of unknown significance to MM and from MM to plasma cell leukemia. 4, 11, 12 Consistent with these findings, hypermethylation of many genes (for example, CDKN2A, CDKN2B, p16, p53, SOCS, RASD1, BNIP3, SPARC, DAPK, CDH-1, CD9, WIF, DKK3, ARF or TGFβR2) correlates with poor prognosis in MM. [12] [13] [14] The molecular mechanism(s) mediating aberrant DNA methylation in MM and its correlation with adverse clinical outcome is unclear. Nonetheless, these findings support therapeutic targeting of epigenetic aberrations such as DNA methylation in MM.
DNA methylation is regulated by a family of DNA methyltransferase (DNMT) enzymes DNMT1, DNMT3A or DNMT3B. 15 Importantly, DNMTs have been targeted in therapeutic approaches: specifically, DNMT inhibitors 5-azacytidine (AZA) and decitabine are FDA-approved for the treatment of hematological malignancies, myelodysplasia and acute myeloid leukemia. 16 Recent research efforts have led to the discovery and development of a novel first-in-class oxidative epigenetic agent RRx-001 with a distinct mechanism of action compared with AZA or decitabine. [17] [18] [19] RRx-001 allosterically modifies hemoglobin and under hypoxic conditions, catalyzes the reduction of nitrite to bioavailable nitric oxide, which accumulates in poorly oxygenated tumors. 19 Nitric oxide rapidly combines with excess superoxide in the hypoxic tumors to trigger high levels of peroxynitrite (ONOO − ), thereby causing oxidative stress ( Figure 1 ). Thus, RRx-001 exerts redox and metabolic stress on tumors, which in turn inhibits DNMTs and global hypermethylation, as well as restores tumor suppressor gene function.
Preclinical studies of RRx-001 have demonstrated anti-tumor activity in refractory solid tumor models. 16, 17 A phase-1 clinical trial of RRx-001 in advanced solid tumors showed promising antitumor activity in a heavily pretreated population, without doselimiting toxicities. 20 RRx-001 is currently under investigation in multiple phase II clinical trials, alone or in combination, for the treatment of solid tumors (NCT02096354; NCT02489903; NCT02452970; NCT02215512). Here, we examined the anti-MM activity of RRx-001 using both in vitro and in vivo preclinical models of MM.
Cell migration, angiogenesis assays and western blotting
Twenty-four-well Transwell plates (Millipore, Billerica, MA, USA) were used to perform cell migration assays as previously described. 24 Angiogenesis was measured, as previously described. 24 Immunoblot analysis was performed using antibodies against caspase-8, caspase-9, caspase-3, PARP, ATM, p53, ku70, γ-H2AX, HDM2, p21, DNMT1 or GAPDH (Cell Signaling, Beverly, MA, USA) DNMT3a or DNMT3b (Bethyl Laboratories, Montgomery, TX, USA). Assessment of reactive oxygen species (ROS), nitric oxide (NO), mitochondrial membrane potential (ΔΨm), nitrosylation and nitrotyrosine levels Cellular ROS and NO levels were detected using assay kits (Abcam, Cambridge, MA, USA). ΔΨm was measured using MitoPT JC-1 assay kit (Thermofisher Scientific, Cambridge, MA, USA). Nitrosylation plus nitrotyrosine modification of proteins was analyzed using (S-NO) detection assay kit and OxiSelect Nitrotyrosine ELISA kit (Oxiselect kit-Cell Biolabs, San Diego, CA, USA).
Transfection assays
MM.1S cells were transiently transfected with control scr-siRNA, DNMT1-siRNA, DNMT3A-siRNA, DNMT3B flexitube siRNA or USP7-siRNA using the cell line Nucleofector kit V (Amaxa Biosystems, Cologne, Germany).
DNMT activity assays
EpiQuik DNA methyltransferase activity kit was utilized to measure total DNMT activity. Global DNA methylation was assessed using MethylFlash Methylated DNA 5-mC Quantification Kit (Epigentek, Farmingdale, NY, USA).
Human plasmacytoma xenograft model
All animal experiments were approved by and conformed to the relevant regulatory standards of the Institutional Animal Care and Use Committee at the Dana-Farber Cancer Institute. CB-17 SCID mice were subcutaneously inoculated with 5.0 × 10 6 MM.1S cells in 100 μl of serum-free RPMI 1640 medium, as previously described. 24 When tumors were measurable, 
Immunohistochemistry
Mice tumor sections were subjected to immunostaining for Ki67, apoptosis (TUNEL), γ-H2AX, vWF, iNOS and DNMT1 as previously described. 22, 25 Immunostained tissues were imaged by microscopy.
Statistical analysis
Statistical significance was determined by the Student's t test. GraphPad Prism software was used for mice survival studies. Isobologram analysis 26 was performed using the CalcuSyn software program.
RESULTS
RRx-001 inhibits MM cell growth and overcomes resistance to novel and conventional therapies RRx-001 (1-bromoacetyl-3,3-dinitroazetidine) is a novel aerospace industry-derived agent with chemical structure and mechanism of action distinct from alkylating and epigenetic drugs ( Figure 1a ). 19 To examine whether RRx-001 affects the viability of MM cells, we treated human MM cell lines (MM.1S, RPMI-8226, H929, ARP-1, KMS-11, OPM2, LR5, ANBL6.WT), along with cell lines that are resistant to drugs such as dexamethasone (MM.1 R), doxorubicin (Dox40), melphalan (LR5), bortezomib (ANBL6.BR) and hypoxiamediated apoptosis (RPMI-8226) with different concentrations of RRx-001 for 24 h, followed by assessment for cell viability using WST-1 assays. RRx-001 induces a dose-dependent significant (P o 0.05) decrease in viability of all cell lines ( Figure 1b ). A significant increase in RRx-001 anti-MM activity (10-20% increase) was noted under hypoxia versus normoxic settings (MM.1S, RPMI-8226 and DOX-40) ( Supplementary Figure 1 ).
To determine whether RRx-001 affects the viability of purified patient MM cells, purified (CD138+) MM cells were examined from two newly diagnosed (patients #3 and #4) and three refractory MM patients (Figure 1c ), who were treated prior with dexamethasone (patient #1), bortezomib/dexamethasone (patient #5) and lenalidomide/bortezomib/dexamethasone (patient #2). All patient MM cells had a dose-dependent decrease in cell viability with RRx-001 treatment ( Figure 1c ). This shows that RRx-001 can trigger cytotoxicity in bortezomib-, Dex-or lenalidomide-resistant patient tumor cells. In contrast, RRx-001 at the IC 50 (1.25-2.5 μM) for patient MM cells does not significantly affect normal peripheral blood mononuclear cell viability ( Figure 1d ). RRx-001 at high concentrations (7-10 μM) decreases peripheral blood mononuclear cell viability by 30-70%, pointing out that normal cells are not completely refractory to RRx-001. Thus, RRx-001 possesses a favorable therapeutic index in MM.
RRx-001 blocks migration of MM cells and associated angiogenesis
Previous studies showed that migration of MM cells and angiogenesis have an important role in the progression of MM. 27, 28 The effect of RRx-001 on these events was therefore examined using transwell insert systems and in vitro tubule formation assays, respectively. Serum alone (control) increased MM.1S cell migration; importantly, RRx-001 inhibited serumdependent MM.1S cell migration, as reflected by reduced crystal violet-stained cells (Figure 2a , left and right panel). These cells were 495% viable before and after performing the migration assay. These data suggest that RRx-001 may negatively regulate homing of MM cells to BM, as well as egress into the peripheral blood.
To determine whether RRx-001 has anti-angiogenic activity, we used in vitro capillary-like tube structure-formation assays. Specifically, human vascular endothelial cells (HUVECs) plated onto matrigel differentiate and form capillary-like tube structures reflecting in vivo neovascularization. Treatment of HUVECs with RRx-001 decreased tubule formation significantly ( Figure 2b ). These findings suggest that the RRx-001 blocks angiogenesis.
RRx-001 inhibits BMSC-or pDC-induced growth of MM cells BMSCs mediate paracrine growth of MM cells and protect against cytotoxicity of anti-MM agents by cytokine secretion. 29, 30 Treatment of BMSCs (patients 1-3) for 24 h with RRx-001 (5 μM) does not decrease the viability of these cells ( Supplementary Figure 2 ). RRx-001 significantly inhibited BMSC-induced MM.1S cell growth ( Figure 2c ).
Our recent studies have shown the important role of pDCs in MM pathogenesis and drug resistance. 21, 31, 32 We therefore next examined the effect of RRx-001 on pDC-induced MM growth. MM.1S cells and patient pDCs were cultured either alone or together, with or without RRx-001. RRx-001 inhibited pDC-induced MM.1S cell growth significantly ( Figure 2d ). This suggests that RRx-001 not only targets MM cells directly, but also overcomes the cytoprotective effects mediated by the MM-host BM microenvironment.
Mechanism(s) mediating the anti-MM activity of RRx-001 MM.1S and ANBL.6BR cells were treated with RRx-001 for 12 h, and then subjected to cell cycle analysis. RRx-001 induced significant G1 phase growth arrest, with concomitant decrease in S phase in both cell lines ( Figure 3a ). RRx-001 triggered significant apoptosis in MM cells (Figure 3b and c, respectively). RRx-001 triggered a marked increase in PARP and caspase-3 cleavage, a signature event during apoptosis 33 (Figure 3d ). Furthermore, we found that RRx-001 induced activation of both caspase-8 (extrinsic) and caspase-9 (intrinsic)-mediated apoptotic signaling cascades ( Figure 3d ).
RRx-001 decreases ΔΨm, as well as increases reactive oxygen and nitrogen species in MM cells Stress-induced apoptosis is associated with alterations in ΔΨm and release of ROS. The role of ROS, in particular superoxide radical (O 2 -), in mediating apoptosis is well established. 34 As reported earlier, RRx-001 triggers oxidative (ROS/superoxide) and nitrative stress (nitric oxide/RNS) or together termed reactive oxygen and nitrogen species (Figure 1a ). 19, 35, 36 Treatment of MM.1S cells with RRx-001 significantly decreased ΔΨm, with a concomitant increase in both ROS and nitric oxide levels (Figures 4a-c). Furthermore, even short-term (2 h) treatment of MM.1S cells with RRx-001 triggered a robust increase in ROS, O2 − and nitric oxide, as evident from immunofluorescence staining assays ( Figure 4d ). Similar to our observations in MM.1S cells, RRx-001 increases superoxide and NO levels in RPMI-8226 and Dox40 cell lines, albeit to a lesser extent than that observed in MM.1S cells. Moreover, RRx-001 modestly increases ROS in RPMI-8226 cells, and only low levels of ROS were observed in Dox40 cells ( Supplementary Figure 3) .
Nitric oxide regulates the activity of various proteins by S-nitrosylation and/or tyrosine nitration, which in turn modulates transcription, DNA repair and apoptosis. 37, 38 Dysregulation of S-nitrosylation is linked to tumorigenesis and drug resistance in cancers. 39 We found that RRx-001 enhances S-nitrosylation of proteins in MM cells (Figure 4e ). Similarly, modification of proteins at 3-nitrotyrosine (NO2-Tyr) residues in RRx-001-treated MM cells confirmed nitric oxide-mediated downstream oxidative stress signaling in MM cells ( Figure 4f ). Together, these findings suggest that anti-MM activity of RRx-001 is mediated via induction of ROS/ nitric oxide/protein modification pathways.
RRx-001 triggers DNA damage response via γ-H2AX/ATM/p53/ Ku70 signaling cascade ROS generation is associated with induction of DNA damage signaling. 40, 41 An early event in the response of mammalian cells to DNA double-strand breaks is the phosphorylation of histone H2AX (γ-H2AX) at the sites in proximity to DNA breaks. 42 RRx-001 triggered upregulation of γ-H2AX ( Figure 4g ). Of note, baseline γ-H2AX levels (untreated control) were observed in MM.1S cells, reflecting ongoing DNA damage in MM cells as reported in our recent study. 43 As for γ-H2AX, DNA damage response proteins ATM and p53 showed similar kinetics of induction in RRx-001treated cells (Figure 4g ). A modest induction of DNA repair protein Ku70 was also noted in RRx-001-treated MM.1S cells (Figure 4g ).
We next determined whether RRx-001-induced cytotoxicity is irreversible. For these studies, we performed drug-washout experiments. MM.1S cells were treated with RRx-001 for short interval (3 h); cells were then washed to remove drugs and cultured in medium without drugs for 24 h. Results showed that short-term (3 h) treatment with RRx-001 triggered significant cytotoxicity in MM.1S cells ( Figure 4h ). These data are consistent with the ability of RRx-001 to trigger ROS/NO and DNA damage within 2 h in MM cells ( Figure 4d and data not shown). Washout experiments showed that a short-time exposure of MM cells to RRx-001 is sufficient to initiate ROS/NO-associated apoptotic signaling and cytotoxicity.
RRx-001 inhibits DNA methylation by downregulating DNMTs Our data ( Figure 4) show that RRx-001 triggers oxidative stress, which in turn can modulate epigenetic events via DNMTs. RRx-001 significantly decreased DNMT activity (Figure 5a , bar graph). In agreement with these data, RRx-001-treated MM.1S cells showed a Human vascular endothelial cells were cultured in the presence or absence of RRx-001 for 12 h, and then assessed for in vitro angiogenesis using matrigel capillary-like tube structure-formation assays (left panel). Image is representative from three experiments with similar results. In vitro angiogenesis is reflected by capillary tube branch formation (dark brown). (Right panel) The bar graph represents quantification of capillary-like tube structure formation in response to indicated agents: branch points in several random view fields/well were counted, values were averaged and statistically significant differences were measured using Student's t test. (c) MM.1S cells were cultured with or without BMSCs for 24 h in the presence or absence of RRx-001, and DNA synthesis was measured by 3 H-TdR uptake (mean ± s.d. of triplicate cultures; Po 0.001 for all samples). (d) MM.1S cells were cultured with or without pDCs for 24 h in the presence or absence of RRx-001, and cell growth was assessed using WST-1 assay (mean ± s.e. of triplicate cultures; Po0.001 for all samples).
marked decrease in the expression of DNMT1, DNMT3A and DNMT3B (Figure 5a , immunoblot). RRx-001 decreases global methylation levels in MM cells in a dose-dependent manner (Figure 5b ).
We next asked whether DNMTs are functionally significant in MM. We performed loss-of-function studies using siRNA against DNMT1, DNMT3A and DNMT3B. The specificity of DNMT1-siRNA, DNMT3A-siRNA or DNMT3B-siRNA was evident by a substantial decrease in the expression of respective DNMTs (Figure 5c , western blot). Importantly, transfection of DNMT1-siRNA, but not scr-siRNA, induced a significant (50 ± 3.2%) MM cell death (Figure 5c , bar graph; P o 0.001). On the other hand, DNMT3B-siRNA triggered a modest (15-20%) cell death, whereas DNMT3A-siRNA-transfected MM cells showed no significant cytotoxicity (Figure 5c , bar graph). Similar findings were observed for DNMT1-siRNA in RPMI-8226 and DOX-40 cells ( Supplementary Figure 4) . Together, these data show that DNMT1 has a key role in MM cell survival versus DNMT3a or DNMT3b. To corroborate these data, we utilized a biochemical inhibitor of DNMT1-procainamide. 44 In concert with our RNA interference data, treatment of MM cells with procainamide decreased MM cell viability (Figure 5d ), which was associated with reduced DNMT activity (Figure 5e ), and global DNA methylation levels (Figure 5f ).
The finding that DNMT1 has a key role in MM (Figure 5c , bar graph), coupled with the data that RRx-001 downregulates DNMT1, suggests a potential role of DNMT1 in RRx-001mediated anti-MM activity. To test this hypothesis, MM.1S cells were transfected with DNMT1-siRNA or scr-siRNA, and then treated with RRx-001, followed by cell viability analysis. DNMT1-siRNA-transfected MM.1S cells showed significant cell death (50%), which was not enhanced in response to treatment with RRx-001 ( Figure 5g ). In contrast, DNMT3B-siRNA-transfected cells showed modest (15-20%) killing, which was markedly increased (50%) upon treatment with RRx-001 ( Figure 5g ). DNMT3A-siRNA triggered only minimal (5%) cytoxicity, and RRx-001 treatment increased (55%) cytotoxicity (Figure 5g ). Our findings that DNMT1 blockade alone triggers cytotoxicity in MM cells is consistent with the similar observations in a recent report. 45 Furthermore, our prior study demonstrated efficacy of pan-DNMT inhibitor AZA in MM cells. 46 A comparative cytotoxicity analysis of RRx-001 with AZA showed that RRx-001 is more potent than AZA against MM cells (Supplementary Figure 5) .
We also examined whether baseline expression of DNMT1 dictates sensitivity to RRx-001. Among DNMTs, DNMT1 was highly expressed, albeit differentially in all MM cell lines. Whereas low and variable expression of DNMT3a and DNMT3b was noted in all cell lines (Supplementary Figure 6A ). Immunoblot analysis of protein lysates shows a higher baseline level of DNMT1 in RPMI-8226 and Dox40 versus MM.1S cells; and importantly, treatment of these cell lines with their respective IC 50 of RRx-001 reduces DNMT1 levels (Supplementary Figure 6B) . These data demonstrate that RRx-001 retains the ability to decrease DNMT1 levels irrespective of differential baseline levels of DNMT1 levels in MM cell lines. Taken together, our data show that: (i) DNMT1-siRNA induces cytotoxicity in MM cells; and importantly, the extent of cytotoxicity induced upon DNMT1 knockdown is similar to that Excitation/Emmission: 490/525 nm, 550/620 nm and 650/670 nm, respectively. Images were obtained with a Leica SP5X laser scanning confocal microscope (×100 magnification). (e) MM.1S cells were treated with DMSO control or RRx-001 for 12 h; cytosolic protein extracts were then subjected to immunoblot analysis using antibodies specific against S-nitrosylated proteins and GAPDH. Blots shown are representative of three independent experiments with similar results. (f) MM.1S cells were treated with DMSO control or RRx-001 for 12 h; total cell lysates were then incubated with tetranitromethane for nitration, followed by analysis of 3-nitrotyrosine levels using the OxiSelect Nitrotyrosine ELISA kit (mean ± s.e.; P o0.005; n = 3). (g) MM.1S cells were treated with DMSO control or RRx-001 for 12 h; protein lysates were then subjected to immunoblot analysis using antibodies specific against γ-H2AX, ATM, p53, Ku70 or β-actin. Blots shown are representative of three independent experiments with similar results. (h) MM.1S cells were treated with DMSO control or RRx-001 for 3 h; cells were washed to remove drugs and then cultured in fresh complete medium for 24 h, followed by analysis of viability using WST-1 assay (mean ± s.e.; P o0.005, n = 3). In addition, cells were treated with RRx-001 continuously for 24 h, and then subjected to analysis viability (mean ± s.d.; P o0.005, n = 3).
Epigenetic modulator RRx-001 as myeloma therapy triggered by RRx-001; (ii) DNMT1 knockdown does not add to the cytotoxic effects of RRx-001; and (iii) RRx-001 downregulates DNMT1. These findings suggest that RRx-001-triggered apoptosis in MM cells is mediated, at least in part, via DNMT1 inhibition.
Deubiquitylating enzyme USP7 stimulates DNMT1 activity and blockade of USP7 enhances anti-MM activity of RRx-001 Analysis of DNMT1-associated proteins using STRING protein interaction database 47 showed a direct interactive link with deubiquitylating enzyme USP7 (Figure 6a ). Deubiquitylating enzymes remove the ubiquitin from proteins, thereby preventing their degradation. An earlier report showed that USP7 stabilizes DNMT1 and upregulates its enzymatic activity. 48 Our data show that RRx-001 decreases DNMT1 activity ( Figure 5 ). On the basis of these observations, we asked whether RRx-001-mediated decrease in DNMT1 is due to a direct inhibitory effect of RRx-001 on USP7. No significant USP7 inhibition was observed in RRx-001-treated MM cells (data not shown). USP7-siRNA decreased DNMT1 activity in MM.1S cells (Figure 6b, bar graph) . Next, we studied whether USP7 inhibition enhances activity of RRx-001 by triggering a more pronounced decrease in DNMT1 activity. Importantly, treatment of USP7-siRNA-transfected cells with RRx-001 showed a more robust cytotoxicity than triggered by either USP7-siRNA or RRx-001 alone (Figure 6c ). To further confirm our findings with USP7-siRNA, we utilized USP7 inhibitor P5091 and examined whether the combination of RRx-001 with P5091 induces additive anti-MM activity. MM.1S, ARP-1 and RPMI-8226 cells were treated with RRx-001 and P5091 across a range of concentrations. Analysis of synergistic anti-MM activity by the Chou and Talalay method 26 showed a significant decrease in viability of all cell lines with combined RRx-001 and P5091, compared with either agent alone (Figure 6d and Supplementary Figure 7) . A combination index of o 1.0 in all MM cell lines tested confirmed the synergistic anti-MM activity. Importantly, combined RRx-001 and P5091 triggered greater DNMT1 inhibition than either agent alone (Figure 6e ). Our earlier study showed that P5091-induced cytotoxicity is primarily mediated by a decrease in USP7 substrate HDM2 and concomitant upregulation of p53 and p21. 22 Combination of RRx-001 and P5091 markedly decreased HDM2, upregulated p53 and p21 versus either agent alone (Figure 6f ).
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RRx-001 inhibits MM cell growth in vivo and prolongs survival in a xenograft mouse model
Having shown that RRx-001 induces apoptosis in MM cells in vitro, we next examined the in vivo efficacy of RRx-001 treatment using the human plasmacytoma MM.1S xenograft mouse model. 22, 24, 25 Treatment of MM.1S-tumor-bearing mice with intravenous injection of RRx-001 blocks MM tumor growth and enhances survival (Figures 7a and b) . RRx-001 treatment was well tolerated, suggested by no apparent weight loss ( Supplementary Figure 8) .
As seen in Figures 7c and d, tumors from RRx-001-treated mice versus control mice showed that RRx-001: (i) increases the number of TUNEL-positive apoptotic tumor cells; (ii) decreases proliferation in tumors, as assessed by Ki67 staining; (iii) reduces angiogenesis, as evidenced by decreased staining for angiogenesis-related vWF; (iv) increases γ-H2AXand iNOS-positive tumor cells; and (v) inhibits DNMT1 expression and enzymatic activity. This shows robust in vivo apoptotic activity of RRx-001.
Combined treatment with RRx-001 and bortezomib, pomalidomide or HDAC inhibitor SAHA induces synergistic anti-MM activity As the mechanism of action of RRx-001 is distinct from anti-MM agents, we next examined whether combining RRx-001 with these agents enhances cytotoxicity via induction of multiple apoptotic signaling pathways. Isobologram analysis 26 to assess synergistic anti-MM activity showed that low concentration combinations of RRx-001 with bortezomib, pomalidomide or HDAC inhibitor SAHA triggers synergistic activity ( Supplementary Figures 9-11) . A concrete evidence of toxicity reduction with combination therapy awaits clinical trials results, but the synergy observed in vitro may suggest for use of lower doses with decreased side effects.
DISCUSSION
Our studies utilized MM cell lines, patient tumor cells and xenograft models, along with biochemical and genetic models, to show the anti-MM activity of a novel epigenetic modulator RRx-001. We show that RRx-001 decreased the viability of MM cell lines and primary patient tumor cells without markedly affecting the viability of normal peripheral blood mononuclear cells. These data suggest a selective anti-MM activity and a favorable therapeutic index for RRx-001. We found anti-MM activity of RRx-001 against various MM cell lines, including those sensitive and resistant to known drug therapies, as well as harboring distinct cytogenetic background. 49, 50 The variable IC 50 of RRx-001 against these MM cell lines may be due to various factors such as distinct genetic profile, drug resistance characteristics, 30 differential sensitivity to oxidative stress or antioxidant capacity among the MM cell lines. For example, we observed a relatively higher IC 50 of RRx-001 for Dox40 and RPMI-8226 versus MM.1S. Another possibility is that because histone deacetylases, in particular HDAC1, modulates DNMT1, 51 it is likely that RRx-001 may alter HDAC1 or other similar upstream regulators of DNMTs. The expression and/or activity levels of upstream modulators of DNMTs among MM cell lines may also account for differential sensitivity to RRx-001. Nonetheless, RRx-001 triggers cytotoxicity in all MM cell lines at the concentrations that are clinically achievable.
To determine whether RRx-001 overcomes bortezomib resistance in MM cells, we utilized previously characterized 52 bortezomib-sensitive (ANBL6.WT) and -resistant (ANBL6.BR) MM cell lines. RRx-001 showed significant anti-MM activity in ANBL6.BR cells, confirming the ability of RRx-001 to overcome bortezomib resistance. Moreover, we found consistently low IC 50 of RRx-001 against tumor cells from patients with MM resistant to bortezomib, lenalidomide and dexamethasone. We found that RRx-001 inhibits MM cell growth, even in the presence of BMSCs or other (c) Tumor sections from vehicle control-and RRx-001-treated mice were subjected to immunostaining using TUNEL, anti-Ki67, anti-vWF, anti-γ-H2AX or anti-iNOS Abs. All Images were obtained with a Leica SP5X laser scanning confocal microscope (40× magnification). Micrographs shown are representative of similar observations in two mice receiving the same treatment. (d) Micrograph: tumors harvested from mice were immunostained with anti-DNMT1 Ab. Bar graph: protein extracts from harvested tumors were analyzed for total DNMT activity using the EpiQuik DNMT activity kit (mean ± s.d.; P o0.005 n = 3). Immunoblot: tumor lysates from control-and RRx-001-treated mice were subjected to immunoblot analysis using anti-DNMT1 or anti-GAPDH Abs.
BM accessory cells including pDCs. Thus, RRx-001 overcomes drug resistance in MM. Moreover, RRx-001 treatment decreases the viability of p53-null ARP-1 MM cells (Figure 1b ). As 10-15% of MM patients at diagnosis have drug resistance conferring p53 mutations/deletions, and these abnormalities are acquired with disease progression, a therapeutic approach using RRx-001 would possess activity even in this setting.
Mechanistic studies show that RRx-001-triggered apoptosis is associated with activation of caspases and PARP; release of reactive oxygen and nitrogen species; induction of DNA damage response signaling via ATM/p53/γH2AX/p21; post-translational modification of proteins via S-nitrosylation or tyrosine nitration and decrease in DNMT1 activity along with global methylation levels. Our finding in MM cells is consistent with similar observations using RRx-001 in other cell systems. 53, 54 Induction of ROS affects DNA methylation by directly interacting with DNA molecules and/or by altering levels of DNMTs; 55 consistent with these data, we found that RRx-001-induced ROS is associated with decreased expression of DNMT1, DNMT3A and DNMT3B. Among DNMTs, DNMT1 is more functionally relevant in MM, because DNMT1-siRNA triggered significant cell death. The DNMT1-inhibitory activity of RRx-001 is clinically relevant in MM because: (i) DNMT1 is highly expressed in MM and correlates with disease progression; 56 (ii) many tumor suppressor genes are hypermethylated in MM; 4, 10, 11, 57, 58 and importantly, a recent study showed that DNMT1-siRNA decreased viability and reactivates tumor suppressor genes SOCS1 and p16 in MM cells. 45, 59 The upstream mechanism(s) regulating DNMT1 are less well defined. USP7 inhibition increases ubiquitylation of DNMT1, and its degradation by the proteasome. We found that the combination of RRx-001 and USP7 inhibitor P5091 triggered synergistic anti-MM activity associated with a robust DNMT1 inhibition. Although we observed activation of HDM2/p53 signaling in cells carrying wild-type p53, it may not be the mechanism explaining synergy noted in p53-null or mutant cells. As shown in our study, the anti-MM activity of RRx-001 can be attributed to induction of multiple apoptotic mechanisms, and is not completely dependent on p53. It is therefore likely that RRx-001-induced cell death in p53-null cells occurs via p53-independent pathways. One possibility is the activation of compensatory activity of p63 or p73 in p53-null ARP-1 or p53-mutant RPMI-8226 cells, which can induce downstream p21; both p63 and p73 are regulated by ubiquitination process for stabilization and therefore may be target of USP7 or respond to P5091. In addition, the synergy between RRx-001 and USP7 inhibitor P5091 may be because of the activation of other USP7 downstream targets besides p53. For example, prior studies have shown that knockdown of USP7 prevents rapid inactivation of the anti-proliferative transcription factor, FOXO4, providing a mechanism to impair the pro-survival PI3K/Akt pathway that is commonly activated in MM. 60 Therefore, USP7 inhibitor P5091 can simultaneously both activate pro-apoptotic via FOXO-mediated oxidative stress and inactivate pro-survival PI3K/ Akt pathways. Thus, the synergy noted between RRx-001 and P5091 may be mediated by the induction of pleiotropic apoptotic mechanisms and abrogation of survival pathways. Overall, these data provide the preclinical rationale for evaluating the combination of RRx-001 with USP7 inhibitor in future clinical trials.
As noted above, an additional mechanism of DNMT1 regulation is acetylation, exemplified by an earlier study showing that HDAC inhibitors degrades DNMT1 via acetylation. However, we did not observe DNMT1 acetylation in RRx-001-treated MM cells (data not shown). It is also possible that RRx-001-induced DNA damage activates an epigenetic mechanism requiring recruitment of DNMT1 on DNA and corresponding decrease in free soluble DNMT1 molecules, as seen in RRx-001-treated cells. These and other such mechanism(s) underlying the RRx-001-mediated decrease in DNMT1 remain to be defined.
In vitro studies showing RRx-001 activity were confirmed in vivo using the human MM.1S xenograft mouse model. Substantial reduction of tumor progression and enhancement of survival was observed in RRx-001-treated versus control mice. Our in vivo findings, coupled with our in vitro data showing minimal toxicity of RRx-001 against normal cells, confirmed that MM cells are more sensitive to epigenetic modulation than normal cells. Finally, we show that RRx-001 adds to anti-MM activity of bortezomib, pomalidomide or HDAC inhibitor SAHA, confirming the potential clinical benefit of combining RRx-001 inhibitors with other agents.
Collectively, our preclinical studies demonstrate that DNMT1 has a key role in MM cell survival versus DNMT3a or DNMT3b. Our findings show robust in vitro and in vivo anti-MM activity of RRx-001 is associated with downregulation of DNMTs as well as present the proof of concept for clinical studies of RRx-001, alone and in combination, to improve patient outcome in MM.
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